Dealwatch: US firms lead on household names The Body Shop and Yodel as restructuring returns Elisha Juttla 22 Feb 2024
Breaking barriers: Garrigues tops €450m revenue in milestone for Euro Elite firms Anna Huntley 21 Feb 2024
Revolving Doors: Fried Frank expands London team with Goodwin trio as Orrick faces global losses Elisha Juttla 16 Feb 2024
‘Firing on all cylinders’: Akin sees double-digit growth in revenue and PEP Holly McKechnie 16 Feb 2024
‘Bolder, pragmatic, more proactive’: Regulators bare teeth, but will they bite? Holly McKechnie 16 Feb 2024
Simpson Thacher unveils new London head as office posts double-digit revenue growth Holly McKechnie 15 Feb 2024
‘It’s a differentiating year’: Hogan Lovells sees double-digit growth in revenue and PEP Elisha Juttla 13 Feb 2024
Revolving doors: Moves in disputes and antitrust as Paul Weiss continues sweep of London recruits Alex Ryan 9 Feb 2024
Rising stars: Jaspreet Takhar – ‘EU regulators are preparing an avalanche of new laws that are going to have a monumental impact on pharma and medtech’ Sophie Chan 9 Feb 2024
Taking back control – the post-pandemic landscape for life sciences regulation Sophie Chan 9 Feb 2024
Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’ Sophie Chan 9 Feb 2024
Rising stars: Zina Chatzidimitriadou – ‘It is the one legal area that affects every single one of us and is, above all, human-centred’ Sophie Chan 9 Feb 2024
‘You’d be a brave innovator to ignore the UK’ – why patent work is booming in the post-Brexit UK life sciences market Marie Johansen Nordland 9 Feb 2024
